Back To Schedule
Sunday, June 23 • 9:00am - 5:00pm
SC40: #40: Interdisciplinary Safety Evaluation During Product Development

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Component Type: Tutorial
CE: ACPE 6.50 Knowledge UAN: 0286-0000-19-517-L04-P; CME 6.50; IACET 6.50; RN 6.50

CIOMS VI (2005) states that “causality judgments based on analysis of multiple cases/aggregate data are almost always more meaningful and typically have a greater impact” (than the traditional case-based medical review). The FDA IND safety reporting final rule reflects that position by requiring an expedited IND safety report whenever aggregate analysis indicates that events occur more frequently in the drug treatment group than in a concurrent or historic control group. Further guidance has outlined how early planning for assessment of emerging safety signals and review of aggregated safety data throughout the development program should be driven by multi-disciplinary safety management teams (SMTs). Following product launch, connection of pre-launch investigations to data sources and analytics post-market enable ongoing surveillance, signal detection, and evaluation of benefit-risk. This short course will provide a systematic, coordinated approach to identify, assess and characterize safety topics of interest that enables investigators to develop clinical as well as quantitative understanding of the safety profile. Focus will target the application of appropriate statistical techniques with a safety mindset, as opposed to strict statistical inference, with the emphasis shifted from testing and confirming to exploration, learning, and medical decision-making within a quantitative framework. The goal is to empower the broader cross-disciplinary, cross-regional community to discover and promote practical quantitative solutions for safety evaluation during throughout the product life-cycle. Audience participation will be highly encouraged. This short course will present the work that has been done by the DIA-ASA Interdisciplinary Safety Evaluation scientific working group, TransCelerate, and ICH. An additional registration fee is required for all preconference short courses. Back to DIA 2019 Short Courses

Who should attend?

This short course is designed for individuals from industry and regulatory agencies who practice in the areas of patient safety and pharmacovigilance. Specifically, individuals who routinely evaluate information and perform tasks such as signal detection, signal evaluation, benefit-risk assessment to determine the safety of products in development and on-market are the target for this proposed short course.

Learning Objectives

At the conclusion of this course, participants should be able to:
  • Examine the global regulatory landscape for interdisciplinary safety evaluation;
  • Develop an aggregate safety assessment planning (ASAP) process;
  • Execute ongoing aggregate safety evaluation (OASE), including: Blinded vs. unblinded analyses, static vs. dynamic assessments, and visual analytic methods, integration of data sources and analysis methods.

avatar for Greg Ball

Greg Ball

Senior Principal Biostatistician, Merck & Co., Inc
After graduating from Northwestern University with a bachelor’s in economics, Greg served in the Navy for 4 years and taught high school math and physics for 5 years, before going back to school to get a master’s in applied statistics from Purdue University. Eventually, while... Read More →
avatar for Jacqueline Corrigan-Curay

Jacqueline Corrigan-Curay

Director, Office of Medical Policy, CDER, FDA
Jacqueline Corrigan-Curay, J.D., M.D., serves as Director of the Office of Medical Policy (OMP) in the Center for Drug Evaluation and Research, FDA. OMP is comprised of the Office of Prescription Drug Promotion (OPDP) and the Office of Medical Policy Initiatives (OMPI). Dr. Corrigan-Curay... Read More →
avatar for Jeremy Jokinen

Jeremy Jokinen

Head of Business Capabilities and Innovation, Worldwide Patient Safety, Bristol-Myers Squibb Company
Jeremy is the Head, Business Capabilities and Innovation, Worldwide Patient Safety, for Bristol-Myers Squibb. Jeremy is also active within numerous TransCelerate PV initiatives and is a deputy topic lead for ICH E19. Jeremy has over 20 years of experience as a statistician in early... Read More →
avatar for James Buchanan

James Buchanan

Drug Safety Consultant, Covilance LLC
Dr. Buchanan has been in the pharmaceutical industry working in drug safety for over 30 years. He started his career at Genentech and led the drug safety departments at a number of subsequent companies, Gilead Sciences, Tularik and Nuvelo, before serving as the head of the medical... Read More →

Sunday June 23, 2019 9:00am - 5:00pm PDT
Room 11A San Diego Convention Center 111 W Harbor Drive, San Diego, CA 92101 USA
  Short Course, Tutorial |   01: ClinSafety-PV, Tutorial